uniQure (NASDAQ:QURE) Shares Gap Up – What’s Next?

uniQure N.V. (NASDAQ:QURE)’s share price gapped up prior to trading on Friday . The stock had previously closed at $22.69, but opened at $23.95. uniQure shares last traded at $25.15, with a volume of 914,442 shares traded.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Wall Street Zen lowered uniQure from a “hold” rating to a “sell” rating in a research note on Sunday, January 11th. Wells Fargo & Company reduced their target price on uniQure from $80.00 to $60.00 and set an “overweight” rating for the company in a report on Wednesday, November 12th. The Goldman Sachs Group decreased their price target on uniQure from $56.00 to $38.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 4th. Royal Bank Of Canada lowered their price target on shares of uniQure from $65.00 to $45.00 and set an “outperform” rating on the stock in a report on Monday, November 3rd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of uniQure in a research note on Wednesday, January 14th. Ten equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, uniQure presently has an average rating of “Moderate Buy” and an average target price of $60.82.

uniQure Stock Performance

The stock has a market cap of $1.56 billion, a PE ratio of -5.71 and a beta of 0.68. The company has a debt-to-equity ratio of 0.23, a current ratio of 7.12 and a quick ratio of 7.12. The business has a 50 day moving average price of $24.12 and a two-hundred day moving average price of $28.11.

uniQure (NASDAQ:QURE) last released its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.53). The business had revenue of $3.70 million during the quarter, compared to analysts’ expectations of $4.46 million. uniQure had a negative return on equity of 373.73% and a negative net margin of 1,492.90%. As a group, equities research analysts forecast that uniQure N.V. will post -3.75 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Jack Kaye sold 38,810 shares of the company’s stock in a transaction that occurred on Tuesday, November 4th. The stock was sold at an average price of $30.34, for a total value of $1,177,495.40. Following the sale, the director owned 20,439 shares in the company, valued at $620,119.26. This represents a 65.50% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Robert Gut sold 31,434 shares of the company’s stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $27.26, for a total transaction of $856,890.84. Following the completion of the transaction, the director owned 40,145 shares in the company, valued at approximately $1,094,352.70. The trade was a 43.92% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 102,247 shares of company stock valued at $2,839,298. 4.79% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Jefferies Financial Group Inc. bought a new stake in shares of uniQure in the second quarter worth approximately $29,217,000. JPMorgan Chase & Co. lifted its holdings in uniQure by 471.7% during the second quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company’s stock valued at $25,199,000 after purchasing an additional 1,491,486 shares in the last quarter. Fred Alger Management LLC bought a new position in shares of uniQure in the third quarter worth about $75,320,000. Sofinnova Investments Inc. lifted its holdings in shares of uniQure by 185.5% in the second quarter. Sofinnova Investments Inc. now owns 1,558,356 shares of the biotechnology company’s stock worth $21,723,000 after buying an additional 1,012,585 shares in the last quarter. Finally, Avoro Capital Advisors LLC lifted its position in shares of uniQure by 22.6% in the third quarter. Avoro Capital Advisors LLC now owns 4,444,444 shares of the biotechnology company’s stock worth $259,422,000 after buying an additional 819,444 shares in the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.